Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

Using 'Diagnostics First' Could Help Preserve Effectiveness Of Life-Saving Antibiotics

publication date: May 25, 2016
 | 
author/source: Cepheid

Cepheid Highlights Role of Diagnostics as Valuable Tool in Growing Fight Against Antibiotic Resistance

Cepheid LogoCepheid (Nasdaq: CPHD) have announced the launch of its 'Diagnostics First' campaign to raise awareness for the use of accurate and fast diagnostic tests to inform optimal treatment decisions and avoid over-prescription of the world's limited arsenal of antibiotics.

"Since the introduction of antibiotics in the 1940s, doctors have had to rely on their expertise, intuition, and experience to diagnose patients and initiate antibiotic therapy well before diagnostic test results were available," said David Persing, M.D., Ph.D., Cepheid's Chief Medical and Technology Officer.  "Many lives have been saved by empiric therapy, but we are now seeing the rise of drug-resistant bacteria that may soon be resistant to all known antibiotics. Fortunately, advances in technology have enabled the accurate and fast diagnostics needed to support real-time decision making by healthcare providers to provide the right drug at the right time."

According to the United States Centers for Disease Control and Prevention (CDC), up to 50% of all prescribed antibiotics are not needed, or are not effective as prescribed.1 Over-use of antibiotics has led to the global rise of drug-resistant infections such as carbapenem-resistant Enterobacteriaceae (CREs) and ceftriaxone-resistant Neisseria gonorrhoeae, as well as an upsurge of Clostridium difficile infections.  All of these have been deemed urgent threats by the CDC.  Multi-drug resistant tuberculosis (MDR-TB) and methicillin-resistant Staphylococcus aureus (MRSA), among others, are also cited as serious threats by the CDC and major global health concerns by the World Health Organization.2 Infections from these bacteria lead to over 25,000 deaths annually and 2.5 million additional hospital days in the EU, and over 23,000 deaths per year and 2 million cases of illnesses in the US.3

"Cepheid strongly endorses the important work being done by the CDC, the White House, the World Health Organization and the United Kingdom's Review on Antimicrobial Resistance, among others, to address the rapidly growing threat of drug-resistant organisms while there is still time to act," said John Bishop, Cepheid's Chairman and Chief Executive Officer.  "The objective of Cepheid's 'Diagnostics First' campaign is to further escalate the discussion about the importance of accurate and fast diagnostics as part of the best 'prescription' in this important fight."
Mr. Bishop adds, "It's critical that we all play our part to help target antibiotics where they are needed more precisely, so that we can preserve their value for future generations.  If the improper use of antibiotics continues, it is possible that minor infections could become deadly, much like they were in the pre-antibiotic era."

"As noted in the O'Neill Review on Antimicrobial Resistance, rapid point-of-care diagnostic tests are a central part of the solution to the problem of unnecessary antibiotic use," said Dr. Thierry Naas, Associate Professor in Medical Microbiology at the University of Paris South Medical School, who is currently coordinating the European Joint Programming Initiative on Antimicrobial Resistance.  "We welcome the efforts of Cepheid and others as they continue to innovate and bring these accurate and fast diagnostics into routine clinical use to help ensure patients receive the most appropriate antibiotic therapy."

For more information on Cepheid's GeneXpert Systems or the complete menu of Xpert tests, visit www.cepheid.com


more about the Diagnostics First campaign


Useful links

1 www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf?

2 www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdfwww.who.int/mediacentre/factsheets/fs194/en/

?3 www.cdc.gov/drugresistance/pdf/antibiotic_resistant_fs.pdf


About GeneXpert Systems and Xpert Tests

With more than 10,000 systems in 182 countries, the GeneXpert System is the world's most popular molecular diagnostics' instrument.  The GeneXpert System's modular configuration means that the system is the most scalable available, offering the ability to perform from one to eighty Xpert tests at the same time.  As a result, the GeneXpert System meets the throughput requirements of customers of all sizes - from lower volume point-of-care settings to higher volume reference laboratories - enabling accurate, fast and cost effective test results.
GeneXpert Systems run proprietary Xpert test cartridges.  The Xpert test menu spans healthcare-associated infections, sexual health, critical infectious disease, and oncology, and today offers 23 tests outside the US, and 20 tests in the US.  More information on the GeneXpert System and the Xpert tests is available on our website at www.cepheid.com.

About Cepheid

Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit www.cepheid.com


 



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events